Satoh Toyomi, Yoshikawa Hiroyuki
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Tsukuba
Ibaraki Prefectural Central Hospital, Kasama, Ibaraki, Japan.
Jpn J Clin Oncol. 2016 Aug;46(8):703-10. doi: 10.1093/jjco/hyw069. Epub 2016 Jun 9.
Discussion of fertility-sparing treatment is an important part of pretreatment counseling for young patients with early epithelial ovarian cancer. As a result of late childbearing nowadays, fertility preservation has become a major issue in ovarian cancer patients. The purpose of this review is to update current knowledge on fertility-sparing treatment for early stage epithelial ovarian cancer, which may be useful for pretreatment counseling for reproductive-age patients. The multicenter study data on the fertility-sparing treatment published by Japan Clinical Oncology Group in 2010 confirmed that fertility-sparing surgery is a safe treatment for Stage IA patients with non-clear cell histology and Grade 1 or 2 and suggested that Stage IA patients with clear cell histology and Stage IC patients with non-clear cell histology and Grade 1 or 2 can be candidates for fertility-sparing surgery followed by adjuvant chemotherapy. In the current review, we added the recent case series and review, and discussed the fertility-sparing treatment on young patients with early epithelial ovarian cancer. We need not to change the proposal by the Japan Clinical Oncology Group study, but we should wait for the results of an ongoing prospective study to strongly recommend the proposal of the Japan Clinical Oncology Group study.
对于早期上皮性卵巢癌的年轻患者，讨论保留生育功能的治疗是预处理咨询的重要组成部分。由于如今生育年龄推迟，保留生育功能已成为卵巢癌患者的一个主要问题。本综述的目的是更新关于早期上皮性卵巢癌保留生育功能治疗的现有知识，这可能对育龄患者的预处理咨询有用。日本临床肿瘤学会2010年发表的关于保留生育功能治疗的多中心研究数据证实，保留生育功能手术对于组织学类型为非透明细胞、1级或2级的IA期患者是一种安全的治疗方法，并表明组织学类型为透明细胞的IA期患者以及组织学类型为非透明细胞、1级或2级的IC期患者可作为保留生育功能手术加辅助化疗的候选者。在当前的综述中，我们增加了近期的病例系列和综述，并讨论了早期上皮性卵巢癌年轻患者的保留生育功能治疗。我们无需改变日本临床肿瘤学会研究的提议，但我们应该等待一项正在进行的前瞻性研究的结果，以便强烈推荐日本临床肿瘤学会研究的提议。
